Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Subjective cognitive concern in multiple sclerosis is associated with reduced thalamic and cortical gray matter volumes.

Kletenik I, Alvarez E, Honce JM, Valdez B, Vollmer TL, Medina LD.

Mult Scler J Exp Transl Clin. 2019 Feb 13;5(1):2055217319827618. doi: 10.1177/2055217319827618. eCollection 2019 Jan-Mar.

2.

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL.

Neurology. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.

PMID:
30635477
3.

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis.

Kuerten S, Jackson LJ, Kaye J, Vollmer TL.

CNS Drugs. 2018 Nov;32(11):1039-1051. doi: 10.1007/s40263-018-0567-8. Review.

4.

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V.

Int J MS Care. 2017 Jan-Feb;19(1):16-24. doi: 10.7224/1537-2073.2015-024.

5.

To PLEX or not to PLEX in natalizumab-associated PML.

Tyler KL, Vollmer TL.

Neurology. 2017 Mar 21;88(12):1108-1109. doi: 10.1212/WNL.0000000000003747. Epub 2017 Feb 22. No abstract available.

PMID:
28228561
6.

Autoimmune encephalitis: A more treatable tragedy if diagnosed early.

Vollmer TL, McCarthy M.

Neurology. 2016 May 3;86(18):1655-6. doi: 10.1212/WNL.0000000000002641. Epub 2016 Apr 1. No abstract available.

PMID:
27037233
7.

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

Yan Y, Li Y, Fu Y, Yang L, Su L, Shi K, Li M, Liu Q, Borazanci A, Liu Y, He Y, Bennett JL, Vollmer TL, Shi FD.

Sci China Life Sci. 2016 Dec;59(12):1270-1281. Epub 2016 Feb 26.

8.

Incorporating real-world clinical practice in multiple sclerosis economic evaluations.

McQueen RB, Nair KV, Vollmer TL, Campbell JD.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):869-72. doi: 10.1586/14737167.2015.1081060. Epub 2015 Aug 20.

PMID:
26295727
9.

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group.

J Neurol. 2014 Apr;261(4):773-83. doi: 10.1007/s00415-014-7264-4. Epub 2014 Feb 18.

PMID:
24535134
10.

Glatiramer acetate ameliorates experimental autoimmune neuritis.

Zhang CJ, Zhai H, Yan Y, Hao J, Li MS, Jin WN, Su N, Vollmer TL, Shi FD.

Immunol Cell Biol. 2014 Feb;92(2):164-9. doi: 10.1038/icb.2013.81. Epub 2013 Nov 26.

PMID:
24275856
11.

A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis.

Vollmer TL, Robinson MJ, Risser RC, Malcolm SK.

Pain Pract. 2014 Nov;14(8):732-44. doi: 10.1111/papr.12127. Epub 2013 Oct 24.

PMID:
24152240
12.

Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS.

JAMA Neurol. 2013 Oct;70(10):1315-24. Review.

13.

Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?

Schwartz CE, Quaranto BR, Healy BC, Benedict RH, Vollmer TL.

Arch Phys Med Rehabil. 2013 Oct;94(10):1971-81. doi: 10.1016/j.apmr.2013.05.009. Epub 2013 May 28.

PMID:
23727344
14.

Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.

Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.

Am J Manag Care. 2013 Apr;19(4):278-85.

15.

Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients.

Moberly JB, Ford DM, Zahir H, Chen S, Mochizuki T, Truitt KE, Vollmer TL.

J Neuroimmunol. 2012 May 15;246(1-2):100-7. doi: 10.1016/j.jneuroim.2012.03.007. Epub 2012 Mar 31.

PMID:
22465063
16.

APOE ε4 is associated with exacerbation of cognitive decline in patients with multiple sclerosis.

Shi J, Tu JL, Gale SD, Baxter L, Vollmer TL, Campagnolo DI, Tyry TM, Zhuang Y, Kuniyoshi SM.

Cogn Behav Neurol. 2011 Sep;24(3):128-33. doi: 10.1097/WNN.0b013e31823380b5.

PMID:
21945984
17.

Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.

Bomprezzi R, Schaefer R, Reese V, Misra A, Vollmer TL, Kala M.

Scand J Immunol. 2011 Sep;74(3):219-226. doi: 10.1111/j.1365-3083.2011.02581.x. Erratum in: Scand J Immunol. 2018 Jul;88(1):e12673.

18.

A review of cases of neuromyelitis optica.

Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL.

Neurologist. 2011 Mar;17(2):98-104. doi: 10.1097/NRL.0b013e31820a9d35. Review.

PMID:
21364364
20.

Demyelinating disease and polyvalent human papilloma virus vaccination.

Chang J, Campagnolo D, Vollmer TL, Bomprezzi R.

J Neurol Neurosurg Psychiatry. 2011 Nov;82(11):1296-8. doi: 10.1136/jnnp.2010.214924. Epub 2010 Oct 9. No abstract available.

PMID:
20935322
21.

Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology.

Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, Xiang R, La Cava A, Van Kaer L, Shi FD.

J Exp Med. 2010 Aug 30;207(9):1907-21. doi: 10.1084/jem.20092749. Epub 2010 Aug 9.

22.

B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.

Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, Vollmer TL.

Exp Neurol. 2010 Jan;221(1):136-45. doi: 10.1016/j.expneurol.2009.10.015. Epub 2009 Oct 29.

PMID:
19879259
23.

Nicotinic attenuation of central nervous system inflammation and autoimmunity.

Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ.

J Immunol. 2009 Feb 1;182(3):1730-9.

24.

CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity.

Bai Y, Liu R, Huang D, La Cava A, Tang YY, Iwakura Y, Campagnolo DI, Vollmer TL, Ransohoff RM, Shi FD.

Eur J Immunol. 2008 Jul;38(7):1877-88. doi: 10.1002/eji.200737973.

25.

IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis.

Liu R, Bai Y, Vollmer TL, Bai XF, Jee Y, Tang YY, Campagnolo DI, Collins M, Young DA, La Cava A, Shi FD.

Exp Neurol. 2008 May;211(1):14-24. doi: 10.1016/j.expneurol.2007.11.004. Epub 2007 Nov 22.

PMID:
18353312
26.

A new EAE model of brain demyelination induced by intracerebroventricular pertussis toxin.

Zhao CB, Coons SW, Cui M, Shi FD, Vollmer TL, Ma CY, Kuniyoshi SM, Shi J.

Biochem Biophys Res Commun. 2008 May 23;370(1):16-21. doi: 10.1016/j.bbrc.2008.02.161. Epub 2008 Mar 11.

PMID:
18339308
27.

IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis.

Piao WH, Jee YH, Liu RL, Coons SW, Kala M, Collins M, Young DA, Campagnolo DI, Vollmer TL, Bai XF, La Cava A, Shi FD.

Scand J Immunol. 2008 Jan;67(1):37-46.

28.

Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis.

Piao WH, Wong R, Bai XF, Huang J, Campagnolo DI, Dorr RT, Vollmer TL, Shi FD.

J Immunol. 2007 Dec 1;179(11):7415-23.

29.

CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis.

Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, Rodebaugh R, Campagnolo DI, Shi FD, Vollmer TL.

Clin Immunol. 2007 Oct;125(1):34-42. Epub 2007 Jul 16.

PMID:
17632037
30.

APOE epsilon 4 allele is associated with cognitive impairment in patients with multiple sclerosis.

Shi J, Zhao CB, Vollmer TL, Tyry TM, Kuniyoshi SM.

Neurology. 2008 Jan 15;70(3):185-90. Epub 2007 Apr 25.

PMID:
17460153
31.

Cell cycle activation in postmitotic neurons is essential for DNA repair.

Schwartz EI, Smilenov LB, Price MA, Osredkar T, Baker RA, Ghosh S, Shi FD, Vollmer TL, Lencinas A, Stearns DM, Gorospe M, Kruman II.

Cell Cycle. 2007 Feb 1;6(3):318-29. Epub 2007 Feb 27.

PMID:
17297309
32.

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.

Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, Vollmer TL, Mandler RN, Dietrich DW, Fletcher M, Pope LE, Berg JE, Miller A; Psuedobulbar Affect in Multiple Sclerosis Study Group.

Ann Neurol. 2006 May;59(5):780-7.

PMID:
16634036
33.

Autoreactive T cells mediate NK cell degeneration in autoimmune disease.

Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, Collins M, Young DA, Vollmer TL, Shi FD.

J Immunol. 2006 May 1;176(9):5247-54.

34.

Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?

Jee Y, Liu R, Bai XF, Campagnolo DI, Shi FD, Vollmer TL.

Int Immunol. 2006 Apr;18(4):537-44. Epub 2006 Feb 15.

PMID:
16481342
35.

Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia.

Liu R, La Cava A, Bai XF, Jee Y, Price M, Campagnolo DI, Christadoss P, Vollmer TL, Van Kaer L, Shi FD.

J Immunol. 2005 Dec 15;175(12):7898-904.

36.

Quantification of multiple sclerosis lesion load and brain tissue volumetry using multiparameter MRI: methodology and reproducibility.

Ding Z, Preiningerova J, Cannistraci CJ, Vollmer TL, Gore JC, Anderson AW.

Magn Reson Imaging. 2005 Apr;23(3):445-52.

PMID:
15862645
37.
38.

Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen.

Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD.

J Immunol. 2005 Mar 1;174(5):2696-701.

39.

Prevalence and treatment of spasticity reported by multiple sclerosis patients.

Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL.

Mult Scler. 2004 Oct;10(5):589-95.

PMID:
15471378
40.

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.

Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS.

Mult Scler. 2004 Oct;10(5):511-20.

PMID:
15471366
41.

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA; Natalizumab Multiple Sclerosis Trial Group.

Neurology. 2004 Jun 8;62(11):2038-43.

PMID:
15184611
42.

Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and nonveterans.

Vollmer TL, Hadjimichael O, Preiningerova J, Ni W, Buenconsejo J.

J Rehabil Res Dev. 2002 Mar-Apr;39(2):163-74.

43.

Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord.

Kohama I, Lankford KL, Preiningerova J, White FA, Vollmer TL, Kocsis JD.

J Neurosci. 2001 Feb 1;21(3):944-50.

44.

The dynamic link between the integrity of the immune system and zinc status.

Fraker PJ, King LE, Laakko T, Vollmer TL.

J Nutr. 2000 May;130(5S Suppl):1399S-406S. doi: 10.1093/jn/130.5.1399S. Review.

PMID:
10801951
45.

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.

Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M.

Neurology. 1999 Mar 23;52(5):1072-4.

PMID:
10102433
46.

General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease.

Sass KJ, Buchanan CP, Westerveld M, Marek KL, Farhi A, Robbins RJ, Naftolin F, Vollmer TL, Leranth C, Roth RH, et al.

Arch Neurol. 1995 Jul;52(7):680-6.

PMID:
7619024
47.

Coccidioidal antigen reactive CD4+ T-lymphocytes in the cerebrospinal fluid in coccidioides immitis meningitis.

Vollmer TL, Gaiser C, Dell'Oca RL, Porteus M, Steinman L, Stevens DA.

J Med Vet Mycol. 1995 Jan-Feb;33(1):43-8.

PMID:
7544405
48.

Ocular myasthenia: a protean disorder.

Weinberg DA, Lesser RL, Vollmer TL.

Surv Ophthalmol. 1994 Nov-Dec;39(3):169-210. Review.

PMID:
7878520
49.
50.

Human immunodeficiency virus-associated motor axonal polyradiculoneuropathy.

Goldstein JM, Azizi SA, Booss J, Vollmer TL.

Arch Neurol. 1993 Dec;50(12):1316-9.

PMID:
8257309

Supplemental Content

Loading ...
Support Center